EUVIMEDEUVIMED entdecken
Crossref

Baxdrostat (Baxfendy) — An Aldosterone Synthase Inhibitor for Hypertension

The Medical Letter on Drugs and Therapeutics · 06.07.2026 · 68 (1758) · 105-106

DOI: 10.58347/tml.2026.1758a ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, online erschienen am 06.07.2026.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The FDA has approved baxdrostat (Baxfendy – AstraZeneca), an oral aldosterone synthase inhibitor, for add-on treatment of hypertension in adults whose blood pressure is not adequately controlled on other drugs. Baxdrostat is the first aldosterone synthase inhibitor to become available in the US.

Schlagwörter

Stichwörter der Autor:innen

ACE inhibitorARBsBaxfendyTryvioadverse effectsaliskirenaprocitentanbaxdrostatchlorthalidonediureticsdosagedrug interactionsefficacyeplerenonehydrochlorothiazide

Zitieren

APA

(2026). Baxdrostat (Baxfendy) — An Aldosterone Synthase Inhibitor for Hypertension. The Medical Letter on Drugs and Therapeutics, 68(1758), 105-106. https://doi.org/10.58347/tml.2026.1758a

Vancouver

Baxdrostat (Baxfendy) — An Aldosterone Synthase Inhibitor for Hypertension. The Medical Letter on Drugs and Therapeutics. 2026;68(1758):105-106. doi:10.58347/tml.2026.1758a

BibTeX
@article{euvimed2026,
  title = {Baxdrostat (Baxfendy) — An Aldosterone Synthase Inhibitor for Hypertension},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2026},
  volume = {68},
  number = {1758},
  pages = {105--106},
  doi = {10.58347/tml.2026.1758a}
}
Kostenlos starten →